Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies
- 1Department of Obstetrics and Gynaecology, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK
- 2Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK
- 3Department of Health Sciences, University of York, Heslington, York, YO1 5DD, UK
- 4Department of Obstetrics and Gynecology, University of Helsinki, 00290, Helsinki, Finland
- 5Department of Obstetrics and Gynecology, University Hospital, 22285, Lund, Sweden
- 6Out-patient Center, Franz Jonas-Platz, A-1210 Vienna, Austria
- 7Department of Obstetrics and Gynecology, National Hospital, N-0027, Oslo, Norway
- Correspondence to: Professor A Templeton, Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, Foresterhill, Aberdeen, AB25 2ZD, UK; allan.templeton{at}abdn.ac.uk
- Accepted 16 August 2002
Abstract
Objective: Screening for Chlamydia trachomatis in the lower genital tract may contribute to the prevention of pelvic inflammatory disease in women. The purpose of this review was to critically appraise, and summarise studies of the cost effectiveness of screening for C trachomatis.
Methods: A literature search was conducted on Medline and in Health Star from 1990–2000. Keywords were C trachomatis, screening, cost effectiveness. Bibliographies of reviewed articles were also searched. The population studied was asymptomatic sexually active women under 30 years of age in a primary care setting. The intervention assessed was screening for lower genital tract infection with C trachomatis and the outcomes studied were cases of C trachomatis detected, cases of PID prevented, and associated costs. Studies were assessed using the Drummond criteria for economic evaluations. They were assessed qualitatively as they were too heterogeneous to allow quantitative analysis.
Results: 10 studies were included. All were modelled scenarios and all found screening to be more cost effective than simply testing symptomatic women, although all were based on probabilities that were assumed. Six of the studies focused on DNA based testing, three of them using urine. The models showed screening to be cost effective at prevalences of 3.1–10.0%, and cost saving (overtesting symptomatic women) at a prevalence as low as 1.1%, if age was used as a selection factor and DNA based tests were used in urine samples.
Conclusions: At the prevalence of infection expected in the target population, all studies suggest screening is cost effective. However, the assumptions used in the models have been difficult to confirm and there is a need for more data, particularly on the risk of complications in women with asymptomatic lower tract infection.
